Its two leading candidates, TERN-601 and TERN-501 -- both in the anti-obesity field -- are close to entering phase 2 studies. The stock's returns in the next few years will depend on clinical and ...
TERN-601, an oral GLP-1 receptor agonist for obesity, has also shown promise in early clinical trials. The Phase 1 study results revealed: A 4.9% placebo-adjusted weight loss over 28 days at the ...
TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25New ...
TERN-601, an oral GLP-1 receptor agonist for obesity, has also shown promise in early clinical trials. The Phase 1 study results revealed: A 4.9% placebo-adjusted weight loss over 28 days at the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback